STRATA CRITICAL MEDICAL, INC. financials

SRTA CIK 0001779128

Source: EDGAR filings · Built 2026-06-02T04:05:42Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2022FY 2021
Free Cash Flow -58.51M -33.38M -34.46M -37.86M -6.24M -15.91M
EBITDA -14.17M -16.56M -61.01M -47.80M -9.82M -23.50M
Working Capital 106.40M 138.02M 170.77M 191.52M 282.16M 304.92M
Net Debt -27.66M -9.06M -3.35M -23.01M -1.88M -6.30M
Gross Margin 20.86% 20.15% 18.71% 15.24% 16.01% 20.82%
Operating Margin -11.34% -15.34% -30.25% -36.63% -42.80% -47.68%
Net Margin 20.97% -18.60% -24.90% -18.66% 3.14% -79.27%
Return on Equity (ROE) 14.82% -12.30% -23.93% -9.93% 0.27% -13.75%
Return on Assets (ROA) 12.70% -10.64% -19.01% -8.39% 0.23% -11.66%
Current Ratio 6.38× 7.07× 5.81× 8.20× 23.07× 32.99×
Debt-to-Equity 0.01× 0.04× 0.10× 0.07× 0.00× 0.00×
Effective Tax Rate 0.00% 0.00% 2.55% 2.75% -16.44% 8.34%
Cash Conversion Ratio -1.18× 0.09× 0.58× 1.36× -7.79× 0.39×
Accruals Ratio 0.28× -0.10× -0.08× 0.03× 0.02× -0.07×
SBC % of Revenue 9.05% 13.55% 5.55% 5.66% 11.91% 19.04%
CapEx Coverage -5.10× -0.08× -15.34× -50.86× -26.86× -52.58×
Free Cash Flow Per Share $-0.71 $-0.43 $-0.47 $-0.53 $-0.08 $-0.37

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2022FY 2021
P/E Trailing (Diluted) 9.62× 883.00×
P/S 2.12× 2.30× 1.18× 1.76× 25.35× 14.43×
P/B 1.49× 1.52× 1.13× 0.93× 2.14× 2.50×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2022FY 2021
Revenue from Contract with Customer, Excluding Assessed Tax 197.14M 146.82M 225.18M 146.12M 24.62M 50.53M
Cost of Revenue 156.01M 117.23M 183.06M 123.84M 20.68M 40.01M
Gross Profit 41.13M 29.59M
Selling, General and Administrative Expense 60.88M 50.86M
Operating Expenses 63.48M 52.11M -33.23M -36.57M -8.98M -24.94M
Operating Income (Loss) -22.35M -22.52M -68.12M -53.53M -10.54M -24.09M
Income Tax Expense (Benefit) 0 0 -1.47M -772.00K -109.00K -3.64M
Net Income (Loss) Attributable to Parent 41.35M -27.31M -56.08M -27.26M 772.00K -40.05M
Earnings Per Share, Basic $0.50 $-0.35 $-0.76 $-0.38 $0.01 $-0.93
Weighted Average Number of Shares Outstanding, Basic 82.09M 77.50M 73.52M 71.24M 69.76M 42.88M
Earnings Per Share, Diluted $0.50 $-0.35 $-0.76 $-0.38 $0.01 $-0.93
Weighted Average Number of Shares Outstanding, Diluted 82.09M 77.50M 73.52M 71.24M 77.68M 42.88M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2022FY 2021
Cash and Cash Equivalents, at Carrying Value 30.97M 18.38M 27.87M 41.34M 2.60M 6.95M
Assets, Current 126.19M 160.74M 206.26M 218.13M 294.94M 314.45M
Assets 325.47M 256.68M 294.94M 325.02M 335.88M 343.39M
Long-term Debt 0
Liabilities, Current 19.79M 22.73M 35.49M 26.61M 12.78M 9.53M
Liabilities 46.40M 34.74M 60.64M 50.54M 44.51M 52.16M
Stockholders' Equity Attributable to Parent 279.07M 221.94M 234.30M 274.49M 291.37M 291.23M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2022FY 2021
Net Cash Provided by (Used in) Operating Activities -48.91M -2.52M -32.35M -37.13M -6.02M -15.62M
Payments to Acquire Property, Plant, and Equipment 9.60M 30.86M 2.11M 730.00K 224.00K 297.00K
Net Cash Provided by (Used in) Investing Activities 69.75M -1.02M 17.09M 79.34M 4.63M -321.34M
Payments for Repurchase of Common Stock 0 244.00K 0
Net Cash Provided by (Used in) Financing Activities -8.91M -5.76M -76.00K -1.08M -2.96M 332.26M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (SRTA CIK 0001779128), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

ICCC

ImmuCell Corporation

RSI

Rush Street Interactive, Inc.

BCC

Boise Cascade Company